Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 197

The DOI matches its Crossref record.

Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease

Open access
Topol, Eric J., Easton, Donald, Harrington, Robert A., Amarenco, Pierre, Califf, Robert M., Graffagnino, Carmen, Davis, Stephen, Diener, Hans-Christophe, Ferguson, James, Fitzgerald, Desmond, Granett, Jeffrey, Shuaib, Ashfaq, Koudstaal, Peter J., Theroux, Pierre, Van de Werf, Frans, Sigmon, Kristina, Pieper, Karen, Vallee, Marc, Willerson, James T. · 2003 · Circulation

Abstract

Background— This is the primary report of the large-scale evaluation of lotrafiban, an orally administered IIb/IIIa receptor antagonist, a unique trial with respect to the platelet antagonist, protocol design, and inclusion of cerebrovascular disease in a significant proportion of patients. Methods and Results— Patients with vascular disease were randomized to lotrafiban 30 or 50 mg BID on the basis of age and predicted creatinine clearance or placebo in addition to aspirin at a dose ranging from 75 to 325 mg/d at the discretion of the physician-investigator. Follow-up was for up to 2 years. The primary end point was the composite of all-cause mortality, myocardial infarction, stroke, recurrent ischemia requiring hospitalization, and urgent revascularization. Of 9190 patients enrolled from 23 countries and 690 hospitals, 41% had cerebrovascular disease at the time of entry, and 59% had coronary artery disease. Death occurred in 2.3% of placebo-assigned patients and 3.0% of lotrafiban-group patients (hazard ratio 1.33, 95% CI 1.03 to 1.72, P =0.026), and the cause of excess death was vascular related. There was no significant difference in the primary end point (17.5% compared with 16.4%, respectively; hazard ratio 0.94, 95% CI 0.85 to 1.03, P =0.19). Serious bleeding was more frequent in the lotrafiban group (8.0% compared with 2.8%; P <0.001). Serious bleeding was more common among patients who received higher doses of aspirin (>162 mg/d), with or without lotrafiban. Conclusions— Lotrafiban, an orally administered platelet glycoprotein IIb/IIIa blocker, induced a 33% increase in death rate, which was vascular in origin and not affected by the type of atherosclerotic involvement at entry to the trial. Although the dose of aspirin was not randomly assigned, the finding of increased bleeding with doses >162 mg/d is noteworthy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000084501.48570.f6

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 197

Metadata

Authors
Topol, E. J., Easton, D., Harrington, R. A., Amarenco, P., Califf, R. M., Graffagnino, C., Davis, S., Diener, H.-C., Ferguson, J., Fitzgerald, D., Granett, J., Shuaib, A., Koudstaal, P. J., Theroux, P., Van de Werf, F., Sigmon, K., Pieper, K., Vallee, M., & Willerson, J. T.
Venue
Circulation
Published
2003-07-29
Volume
108
Issue
4
Pages
399-406
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2124720149
Cited by
197
References
0
FWCI
11.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease. https://app.cochat.ai/papers/10.1161/01.cir.0000084501.48570.f6
The paper
Topol, E. J., Easton, D., Harrington, R. A., Amarenco, P., Califf, R. M., Graffagnino, C., Davis, S., Diener, H.-C., Ferguson, J., Fitzgerald, D., Granett, J., Shuaib, A., Koudstaal, P. J., Theroux, P., Van de Werf, F., Sigmon, K., Pieper, K., Vallee, M., & Willerson, J. T. (2003). Randomized, Double-Blind, Placebo-Controlled, International Trial of the Oral IIb/IIIa Antagonist Lotrafiban in Coronary and Cerebrovascular Disease. Circulation. https://doi.org/10.1161/01.cir.0000084501.48570.f6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.